Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00268216 · ClinicalTrials.gov registry record · Phase 3
Survival Of Subjects With Chronic Obstructive Pulmonary Disease (COPD)
A Phase 3 study of Pulmonary Disease, Chronic Obstructive, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 6,228
- Enrollment target
- 20
- Study locations
NCT00268216 is a Phase 3 study of Pulmonary Disease, Chronic Obstructive that has completed, run by GlaxoSmithKline. The registered enrollment target is 6,228 participants, above the 960-participant average among 74 other Pulmonary Disease, Chronic Obstructive trials with a reported enrollment target (549% higher). The trial reports 20 study locations across 3 states.
The verdict
NCT00268216, a Phase 3 study of Pulmonary Disease, Chronic Obstructive, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 6,228 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to see if fluticasone 500mcg/salmeterol 50mcg can improve the survival of subjects with COPD and also assess the long term safety profile of this drug.
Conditions Studied
Interventions
- DRUG Salmeterol 50mcg/ Fluticasone Propionate 500mcg
Study Locations (20)
California
- GSK Investigational Site - Berkeley
- GSK Investigational Site - Burbank
- GSK Investigational Site - Encinitas
- GSK Investigational Site - Fresno
- GSK Investigational Site - Fullerton
- GSK Investigational Site - Long Beach
- GSK Investigational Site - Los Angeles
- GSK Investigational Site - Los Angeles
- GSK Investigational Site - Rancho Mirage
- GSK Investigational Site - Riverside
- GSK Investigational Site - San Diego
Alabama
- GSK Investigational Site - Birmingham
- GSK Investigational Site - Birmingham
- GSK Investigational Site - Birmingham
- GSK Investigational Site - Jasper
- GSK Investigational Site - Mobile
- GSK Investigational Site - Ozark
Arizona
- GSK Investigational Site - Phoenix
- GSK Investigational Site - Phoenix
- GSK Investigational Site - Scottsdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6,228 participants |
| Start Date | 2000-09 |
| Est. Completion | 2005-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00268216
The ClinicalTrials.gov registry entry for NCT00268216 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 6,228 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 960-participant average among 74 other Pulmonary Disease, Chronic Obstructive trials with a reported enrollment target (549% higher). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pulmonary Disease, Chronic Obstructive appearing as the primary indexed condition, and to 1 intervention - of which Salmeterol 50mcg/ Fluticasone Propionate 500mcg is the first listed.
NCT00268216 reports 20 study locations spanning 3 distinct geographic areas - top geographies include California, Alabama, Arizona.
Frequently Asked Questions
What is clinical trial NCT00268216 about?
NCT00268216 is a clinical study titled "Survival Of Subjects With Chronic Obstructive Pulmonary Disease (COPD)". The purpose of this study is to see if fluticasone 500mcg/salmeterol 50mcg can improve the survival of subjects with COPD and also assess the long term safety profile of this drug.
What is the current status of trial NCT00268216?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 6,228 participants. The study started on 2000-09. Estimated completion is 2005-11.
What conditions does trial NCT00268216 study?
This clinical trial studies the following conditions: Pulmonary Disease, Chronic Obstructive.
What interventions are being tested in trial NCT00268216?
The interventions under investigation include: Salmeterol 50mcg/ Fluticasone Propionate 500mcg (DRUG).
Who is sponsoring clinical trial NCT00268216?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00268216 being conducted?
This trial has 20 study locations across Alabama, Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Disease, Chronic Obstructive
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
RECRUITING · Phase 3
-
eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
RECRUITING · Phase 3
-
Trial to Determine Effective Aspirin Dose in COPD
RECRUITING · Phase 3
-
Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1)
RECRUITING · Phase 3
-
An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444.Study B
COMPLETED · Phase 3
-
A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium Compared With Tiotropium in Subjects With Chronic Obstructive Pulmonary Disease
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.